A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
Julia ManzoShannon PuhallaShalu PahujaFei DingYan LinLeonard ApplemanHussein TawbiRonald StollerJames J LeeBrenda DiergaardeBrian F KieselJing YuAntoinette R TanChandra P BelaniHelen ChewAgustin A GarciaRobert J MorganAndrea E Wahner HendricksonDaniel W VisscherRachel M HurleyScott H KaufmannElizabeth M SwisherSteffi OesterreichTiffany KatzJiuping JiYiping ZhangRalph E ParchmentAlice ChenWenrui DuanVincent GirandaStacie P ShepherdS Percy IvyEdward ChuJan H Beumernull nullPublished in: Cancer chemotherapy and pharmacology (2022)
Continuous veliparib is safe and tolerable. The RP2D was 400 mg BID. There is evidence of clinical activity of veliparib in patients with BRCAmut and BRCAwt cancers.